David H Aggen, MD PhD (@Dr_Aggen) ranks #14 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 28 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: VOLGA, NIAGARA, KEYNOTE-B15 / EV-304. CMS Open Payments lists $10,044 in 2025 general payments.
At a Glance
- 16 posts naming a trial in 2026
- 10 trials discussed by name
- GU Cancer: US #14 · 28 physicians engaged
- Leading physician voice: #1 of 5 physicians on NEXUS-01; #2 of 26 physicians on KEYNOTE-866
- CMS Open Payments lists $10,044 in 2025 general payments.
This Month
What David H Aggen, MD PhD has posted in the last 30 days. Updated November 10, 2026.
Thanks, @LauraBukavinaMD. An important caveat to this data is that central pathology review was not mandated in VOLGA. Some calling of pathCR was done retrospectively. This makes it very difficult to compart pathCR rates across trials - in addition to all the usual caveats of comparing across studies.
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS
VOLGA shows Improved EFS and OS for Durva/EV presented by @tompowles1 #ESMO26 #oncoalert EFS HR 0.51 OS HR 0.58 pCR rate 44% https://t.co/ZpiDvcSSqj
Updated POTOMAC data at #ESMO26 in BCG-naïve high-risk NMIBC from Maria De Santos: Adding durvalumab to BCG improved DFS (HR 0.68), with encouraging results in T1 disease (HR 0.48) and cystectomy-free survival (HR 0.45). Key question: Is the incremental benefit worth the added toxicity and treatment burden? #ESMO2026 @OncoAlert
Volga EFS and OS for Durva/EV and Durva/Treme #ESMO26 #oncoalert https://t.co/lsXejelahv
NIAGARA biomarker analysis at #ESMO26 🧬 DDR alterations (ERCC2, KMT2C, FAT1) associated with higher pCR rates across arms. 📊 Perioperative durvalumab + NAC improved EFS across most molecular subtypes, with greatest apparent benefit in basal-squamous and luminal tumors. 🔬 T-effector/IFNγ-high tumors showed greater pCR gains. Exploratory findings—no validated biomarker to select patients for durvalumab.
Who Amplifies David H Aggen, MD PhD
Physicians who reposted David H Aggen, MD PhD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #14 | — | 28 | 43 | Full ranking |
Trials David H Aggen, MD PhD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| VOLGA | 4 | #3 of 57 | Oct 25, 2026 |
| NIAGARA | 3 | #4 of 32 | Oct 24, 2026 |
| KEYNOTE-B15 / EV-304 | 3 | #5 of 44 | Oct 23, 2026 |
| ENERGIZE (CA017-078) | 2 | #2 of 17 | Oct 23, 2026 |
| KEYNOTE-866 | 2 | #2 of 26 | Oct 23, 2026 |
| POTOMAC | 1 | #6 of 17 | Oct 24, 2026 |
| TROPHY-U-01 | 1 | #4 of 10 | Oct 23, 2026 |
| NEXUS-01 | 1 | #1 of 5 | May 22, 2026 |
| LITESPARK-022 | 1 | #24 of 40 | Mar 1, 2026 |
| LITESPARK-011 | 1 | #36 of 37 | Mar 1, 2026 |
David H Aggen, MD PhD on VOLGA
Thanks, @LauraBukavinaMD. An important caveat to this data is that central pathology review was not mandated in VOLGA. Some calling of pathCR was done retrospectively. This makes it very difficult to compart pathCR rates across trials - in addition to all the usual caveats of comparing across studies.
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS
VOLGA shows Improved EFS and OS for Durva/EV presented by @tompowles1 #ESMO26 #oncoalert EFS HR 0.51 OS HR 0.58 pCR rate 44% https://t.co/ZpiDvcSSqj
David H Aggen, MD PhD on NIAGARA
NIAGARA biomarker analysis at #ESMO26 🧬 DDR alterations (ERCC2, KMT2C, FAT1) associated with higher pCR rates across arms. 📊 Perioperative durvalumab + NAC improved EFS across most molecular subtypes, with greatest apparent benefit in basal-squamous and luminal tumors. 🔬 T-effector/IFNγ-high tumors showed greater pCR gains. Exploratory findings—no validated biomarker to select patients for durvalumab.
5 phase III perioperative MIBC trials, with differing results. EV-303, EV-304 and NIAGARA improved EFS/OS, while ENERGIZE and KEYNOTE-866 did not meet their EFS endpoints. Important differences in patient populations, regimens and trial design. Cross-trial comparisons require caution. #ESMO26 @OncoAlert
KEYNOTE-866: No significant EFS benefit with perioperative pembro + gem/cis (HR 0.88, p=0.14) and no OS signal (HR 1.00). Why did the control arm perform so well? More cT2 disease? No split-dose cisplatin? Important differences vs NIAGARA. #ESMO26 @OncoAlert https://t.co/GWIiavQV7j
David H Aggen, MD PhD on KEYNOTE-B15 / EV-304
Interesting exploratory ctDNA data from EV-304/KEYNOTE-B15 at #ESMO26 in cisplatin-eligible MIBC. 🔹 ctDNA clearance: 82.1% with EV+P vs 66.7% with gem/cis 🔹 Baseline ctDNA+ patients derived substantial EFS benefit from EV+P (HR 0.54) 🔹 Persistent ctDNA positivity after surgery was associated with poor outcomes regardless of treatment. ctDNA is a powerful prognostic biomarker, but can it guide treatment selection or bladder preservation? More work is needed. #BladderCancer #ctDNA
🚨 Updates for MIBC 🚨 FDA approves neoadjuvant + adjuvant EV+pembro for muscle-invasive bladder cancer — regardless of cisplatin eligibility. The first platinum-free regimen to beat SOC chemo in ~25 yrs. EV-304 (KEYNOTE-B15): 📉 EFS HR 0.53 (47% ↓ recurrence/progression/death) 📉 OS HR 0.65 (35% ↓ death) 🔬 pCR 55.8% vs 32.5% Another win for our bladder cancer patients. @BladderCancerUS https://t.co/MBWCeDztr2
UC Takeaways from #ASCOGU26 1) KEYNOTE-B15 is a landmark. Periop EV+pembro vs gem/cis in cis-eligible MIBC: EFS HR 0.53, pCR 55.8% vs 32.5%, OS benefit. First regimen to displace cisplatin in curative-intent bladder cancer in ~25 yrs. https://t.co/VQgB23JeVl
David H Aggen, MD PhD on ENERGIZE (CA017-078)
5 phase III perioperative MIBC trials, with differing results. EV-303, EV-304 and NIAGARA improved EFS/OS, while ENERGIZE and KEYNOTE-866 did not meet their EFS endpoints. Important differences in patient populations, regimens and trial design. Cross-trial comparisons require caution. #ESMO26 @OncoAlert
ENERGIZE: Another negative perioperative IO trial in MIBC. Nivo + GC → cystectomy → nivo failed to improve EFS (HR 0.94, p=0.67). OS HR 0.88. Notably, split-dose cisplatin was allowed and 77% had cT2 disease. Again, excellent outcomes in the control arm. #ESMO26 @OncoAlert https://t.co/9g4zjz7Nq7
David H Aggen, MD PhD on KEYNOTE-866
5 phase III perioperative MIBC trials, with differing results. EV-303, EV-304 and NIAGARA improved EFS/OS, while ENERGIZE and KEYNOTE-866 did not meet their EFS endpoints. Important differences in patient populations, regimens and trial design. Cross-trial comparisons require caution. #ESMO26 @OncoAlert
KEYNOTE-866: No significant EFS benefit with perioperative pembro + gem/cis (HR 0.88, p=0.14) and no OS signal (HR 1.00). Why did the control arm perform so well? More cT2 disease? No split-dose cisplatin? Important differences vs NIAGARA. #ESMO26 @OncoAlert https://t.co/GWIiavQV7j
David H Aggen, MD PhD on POTOMAC
Updated POTOMAC data at #ESMO26 in BCG-naïve high-risk NMIBC from Maria De Santos: Adding durvalumab to BCG improved DFS (HR 0.68), with encouraging results in T1 disease (HR 0.48) and cystectomy-free survival (HR 0.45). Key question: Is the incremental benefit worth the added toxicity and treatment burden? #ESMO2026 @OncoAlert
David H Aggen, MD PhD on TROPHY-U-01
Is it time for triplets in frontline la/mUC? Really enjoyed hearing Randy Sweis present SG + EV + zimberelimab in TROPHY-U-01 Cohort 7. Impressive ORR of 81%, median PFS 19.3 mo (n=21). Promising early data, but larger studies needed to assess added benefit and toxicity. #ESMO26 @OncoAlert
David H Aggen, MD PhD on NEXUS-01
(1/3) NEXUS-01 adds to the growing story that Nectin-4 may remain a relevant target even after EV exposure. Data will be presented at #ASCO26 by @IyerGopa from @MSK_DeptOfMed Although Nectin-4 expression may decrease in EV/P resistant tumors, this data support targeting the antigen with a different payload or MOA Abstract: ASCO NEXUS-01 Abstract https://t.co/kjKJIWynYu #ASCO #BladderCancer #UrothelialCancer #ADC
David H Aggen, MD PhD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
A major challenge for patients on Enfortumab Vedotin for prolonged periods is mitigating neuropathy. We are actively investigating the use of a novel MMAE binder to prevent neuropathy for patients with metastatic urothelial cancer #ESMO26 @BladderCancerUS @urotoday ESMO trial in progress poster here MSK PI Sam Funt https://t.co/i7qjL8QJ9w: https://t.co/YFkGPFfxUe MSK Link: https://t.co/PYAk8CLijd
Expert discussion from @MTeoMD at #ESMO26 https://t.co/G15EJSrhVT
The are likely multiple different resistance mechanisms when cancer progresses after EV/Pembro treatment. Looking forward to @MichalSternsch @MSK_DeptOfMed presenting at #ASCO26 some of the first data with paired biopsies to describe what happens to nectin-4, trop-2, and HER2 post EV/P 🚨abstract: https://t.co/8nIGvhhz2G 🚨
LY405231 a topo-I nectin-4 targeted ADC retains clinical activity post EV/P. Presented by @IyerGopa #ASCO26 ➡️ ORR 42% ➡️ Prior Topo-i exposure 0% (0/18 responses) ➡️ Increwased toxicity in the 7% of patients with low CYP2D6 activity score - one of the first markers of increased toc with a topo-I drug
The post EV/P treatment space is a prospective data free zone. Excited to hear @IyerGopa present data for a novel nectin-4 targeted topo-isomerase payload ADC - LY4052031 at #ASCO26 Nexus-01 is recruiting @MSK_DeptOfMed @UrologyMSK : https://t.co/VdVMMdIgPn https://t.co/mP0hGiQubP
Industry Payments
CMS Open Payments · 2025 general payments
$10,044 across 14 payments